SK bioscience Co.,Ltd. (KOSE: A302440)
Health Care · Biotechnology · KR
₩36,500.00
-3.05% today · -24.1% 1Y
SK bioscience Co.,Ltd. (KOSE: A302440) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.07B.
Over the last twelve months the share price has lost 24.1%, trading between 31.80K and 61.30K.
Tweenvest scores SK bioscience Co.,Ltd. across four factors: quality 63/100, value 69/100. Its strongest factor is value.
A302440 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.07B
- Revenue (TTM)
- $425.71M
- P/E
- —
- EPS
- -1,080.54
- Dividend yield
- —
- Beta (5Y)
- 0.86
- 52-week high
- ₩61,300.00
- 52-week low
- ₩31,800.00
- Avg volume (3M)
- —
- Shares outstanding
- 78.46M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.63 | +0.25% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.01 | +0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.69 | +0.39% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.14 | +0.01% |
| argenx SEENXTBR: ARGX | $65.85B | €882.20 | -2.20% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $142.08 | -2.06% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.